POLYRIZON Shares Surge 38% After Successful PL-14 Intranasal Study
By ATTN Desk · Editorial oversight: Sean Han
Introduction to POLYRIZON LTD
POLYRIZON LTD (NASDAQ: PLRZ) is a development-stage biotechnology company headquartered in Raanana, Israel. The firm focuses on intranasal medical device hydrogels designed to form a thin, protective barrier in the nasal cavity. Its proprietary Capture and Contain™ (C&C) hydrogel technology aims to block viruses and allergens from contacting nasal epithelial tissue. A second platform, Trap and Target™ (T&T), is in preclinical stages for delivering active pharmaceutical ingredients via the nasal route.
| Metric | Value |
|---|---|
| Share Price (09/12/2025) | $1.3495 (+38.06%) |
| Daily Volume | 12,147,608 shares |
| 52-Week Range | $0.55 – $1,200.00 |
| Market Capitalization | $6.05 million |
| Total Cash (mrq) | $2.55 million |
| Net Income (ttm) | –$1.6 million |
| Diluted EPS (ttm) | –125.00 |
| Price/Book (mrq) | 1.14 |
Corporate Structure and Leadership
According to its LinkedIn profile, POLYRIZON employs between two and ten staff. The senior leadership team combines expertise in pharmaceuticals, medical devices, and regulatory affairs:
- Tomer Izraeli, Founder & Chief Executive Officer, B.Sc., MBA, 18 years in device and pharmaceutical development
- Nir Ben Yosef, Chief Financial Officer, CPA, previously CFO of ENvizion Medical Ltd. and partner at Shimony Yosef CPA
- Daphna Avital, Chief People Officer, MA, 20 years in organizational consulting at Allergan and AstraZeneca
- Dr. Tidhar Turgeman, Chief Technology Officer, specialized in drug delivery systems and small-molecule R&D
- Yuliya Yutkevich, QA & RA Director, 15 years in global regulatory compliance and quality systems
- Dr. Eyal S. Ron, Chief Scientific Officer, co-founder of nine companies, former appointee at Harvard-MIT Health Sciences & Technology
Intranasal delivery by Richard Stachmann
Recent Developments and News
On March 31, 2025, POLYRIZON announced a $17.0 million private placement, issuing 35,416,667 ordinary units at $0.48 each, with gross proceeds expected by April 1, 2025. Proceeds are designated for working capital and general corporate purposes.
On July 31, 2025, the company filed a Form 6-K to convene a Special General Meeting of Shareholders on September 4, 2025. Proxy materials outlined proposals for board and governance matters.
On August 14, 2025, a Form 6-K disclosed that POLYRIZON had regained compliance with Nasdaq’s listing requirements.
At the shareholder meeting on September 4, 2025, all proposals were approved, as reported in a subsequent Form 6-K filing.
On September 12, 2025, the company reported successful intranasal delivery of its PL-14 allergy blocker in a proof-of-concept study, indicating progress for its C&C platform.
Financial and Strategic Analysis
POLYRIZON remains in the development stage, with no reported product revenues. As of the latest quarter, the company held $2.55 million in cash against a trailing net loss of $1.6 million. Negative free cash flow of approximately $771,750 year-to-date signifies reliance on financing activities.
The $17.0 million private placement in March 2025 strengthened the balance sheet and supported ongoing R&D efforts. Regaining Nasdaq compliance in August 2025 ensures continued access to public markets. As there is no long-term debt reported, liquidity depends on equity raises and potential partnerships.
Strategically, advancing the C&C and T&T platforms through preclinical and clinical milestones will be vital for company growth. Management's expertise in regulatory affairs and device development is likely to facilitate FDA and CE mark submissions.
Market Position and Industry Context
Intranasal drug delivery is an emerging segment within medical devices and biotechnology, targeting both prophylactic and therapeutic applications. POLYRIZON’s “biological mask” concept engages with existing chemical nasal sprays, vaccines, and emerging barrier technologies. A competitive allergy and viral-protection market necessitates differentiation through clinical data. With a market capitalization of approximately $6 million, the company is among smaller, development-stage peers seeking capital to progress towards first-in-human studies. Strategic collaborations or licensing agreements may be advantageous for scaling manufacturing and expediting commercialization.
TL;DR
On September 12, 2025, POLYRIZON’s share price increased 38.06% to $1.3495 following the study indicating successful intranasal delivery of its PL-14 allergy blocker. Earlier in 2025, the company raised $17.0 million in a private placement (March 31) and regained Nasdaq compliance (August 14). Shareholders approved board and governance proposals on September 4. Future clinical validation of C&C and T&T platforms, along with strategic partnerships, will influence POLYRIZON’s funding needs and market entry timeline.